Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.
|Articles|June 9, 2004
FDA approves ISTA product, asked to evaluate another
On May 6 the FDA approved ISTA Pharmaceutical's new drug application (NDA) for lyophilized, ovine hyaluronidase for injection (Vitrase) for use as a spreading agent to facilitate the dispersion and absorption of other drugs.
Advertisement
Advertisement
Related to this article
In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA requires NAION warning across the GLP-1 receptor agonist class
2
Retinal gene therapy in 2026: 13 milestones from January through October
3
FDA aligns with VeonGen on pivotal phase 3 design for VG801 dual-AAV gene therapy in Stargardt disease
4
Training refractive surgeons and expanding access to eye surgery
5